# Anda Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anda-biopharma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.anda-biopharm.com
- Latest round: Series A (Mar 24, 2025)
- Investors on record: 5

## About

Founded in 2018 and based in Shanghai, China, Anda Biopharma is a developer of AI-driven tumor neoantigen therapies. In March 2025, Anda Biopharma closed a series A funding co-led by new investors Leading Capital and Puxin Capital, new investors Sinan Yuanke, Botong Venture Capital, DFJ DragonFund China, with participation from other strategic investors.
The company focuses on AI-driven tumor neoantigen therapy. It has created the AD-INN technology analysis platform. Its core products include PCNAT-01 (personalized neoantigen vaccine for pancreatic cancer).
The company generates revenue by developing AI-driven tumor neoantigen therapies.
The funding raised in March 2025 will be primarily used to advance the clinical development of PCNAT-01, a personalized tumor neoantigen vaccine in its core pipeline, while also accelerating the preclinical development of other pipeline projects.

## Funding rounds

- Series A, Mar 24, 2025 — DFJ DragonFund China, Leading Capital, Puxin Capital, Sinan Yuanke, Botong Venture Capital

## Investors

- DFJ DragonFund China (https://capitalatlas.ai/funds/dfj-dragonfund-china) — Series A
- Leading Capital — Series A
- Puxin Capital (https://capitalatlas.ai/funds/puxin-capital) — Series A
- Sinan Yuanke (https://capitalatlas.ai/funds/sinan-yuanke) — Series A
- Botong Venture Capital — Series A